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BACKGROUND: Current guidelines recommend that all gastric ulcers (GUs) be biopsied extensively to exclude
underlying malignancy. However, many gastroenterologists opt to also perform surveillance
endoscopy (EGD) to document ulcer healing. The purpose of this study was to examine frequency of
utilization of surveillance EGD in patients found to have GUs using a national endoscopic database.
METHODS: The Clinical Outcomes Research Initiative (CORI) database was used to identify ambulatory patients
diagnosed with a GU between 2001 and 2005. A surveillance EGD was defined as any EGD
performed ≤3 months after index EGD. Results were stratified by patient demographic factors, index
ulcer size and location, practice setting, and geographic region. Multivariate logistic regression was
performed to identify independent predictors of surveillance EGD utilization.
RESULTS: In the database, 6,113 patients met our inclusion/exclusion criteria, of which 1,510 (24.7%)
underwent surveillance EGD. Older patients were more likely to undergo surveillance than younger
patients (P < 0.0001), though a substantial minority (15.2%) of patients <40 years of age
underwent a surveillance examination. Index ulcer size ≥1 cm and care in a Veterans Affairs (VA)
setting were also independent predictors of surveillance EGD utilization. Significant geographic
variation was noted, with surveillance rates varying from 16.0% to 35.9% across the United States
(P < 0.0001).
CONCLUSIONS: In contrast to guideline recommendations, approximately 25% of ambulatory patients diagnosed
with GUs underwent surveillance EGD within 3 months. Notably, patients at low-risk for gastric
cancer, including young patients, those with small index ulcers, and those with antral ulcers,
underwent surveillance at higher than expected rates, which suggests overuse of surveillance EGD.
(Am J Gastroenterol 2008;103:1920–1925)
INTRODUCTION
A gastric ulcer (GU) is defined as a significant break in the
mucosal lining of the stomach. GUs are a common endo-
scopic finding, with a point prevalence as high as 4% and a
lifetime incidence of more than 10% in the general popula-
tion (1–3). During endoscopy (EGD), a small percentage of
these ulcers will appear grossly malignant, prompting biop-
sies and surveillance EGD to document healing. However,
the vast majority of GUs (>90%) appear benign both endo-
scopically and histologically, the result of nonsteroidal an-
tiinflammatory drugs (NSAIDs) and/or Helicobacter pylori
(HP) infection (4, 5). Yet, approximately 5% of endoscopi-
cally benign-appearing GUs are in fact malignant (6–8).
Determining whether an endoscopically benign-appearing
GU is truly benign or malignant can be challenging. One
method for making this distinction is to obtain multiple
biopsies of the ulcer at the time of the index EGD. This
approach has been shown to be highly sensitive for detect-
ing malignancy in both retrospective and prospective tri-
als (8, 9). As a result, the combined American Society of
Gastrointestinal Endoscopy and American College of Gas-
troenterology (ASGE/ACG) Task Force on Quality in En-
doscopy recommends routinely performing biopsies of all
GUs to exclude malignancy (10). Nevertheless, endoscopists
frequently perform surveillance EGD to document GU heal-
ing in order to exclude underlying malignancy. In a sur-
vey of Canadian endoscopists, more than 60% reported that
they perform surveillance EGD routinely in patients with
a GU (11). Overuse of surveillance EGD in patients with
GUs may increase procedure-related complications and costs
and misappropriate limited endoscopic resources. Indeed, not
one of the three major U.S. professional gastroenterology
societies (ASGE, ACG, and American Gastroenterological
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Association [AGA]) specifically recommends performing en-
doscopic surveillance of benign-appearing GUs. Yet, no prior
study has examined how often endoscopists across the United
States perform GU surveillance. In addition, no study has
identified risk factors for utilization of surveillance EGD.
The purpose of this study was (1) to estimate the propor-
tion of patients initially diagnosed with a GU who underwent
surveillance EGD using a national endoscopic database and
(2) to stratify these results by patient demographic factors,
index EGD characteristics, and practice setting.
METHODS
Study Design and Dataset
We performed a retrospective cohort study using data from
the Clinical Outcomes Research Initiative (CORI) database.
The CORI database is a national endoscopic database that
contains data for nearly two million endoscopic procedures
conducted by over 400 endoscopists at more than 80 com-
munity, academic, and Veterans Affairs (VA) sites across
the United States (representing ∼1% of all endoscopies per-
formed nationally in Medicare patients) (12). CORI data are
collected in a structured, prospective fashion (13, 14). Fur-
thermore, these data have been shown to be representative of
national endoscopic practice patterns in Medicare patients in
the United States (12).
Data Collection
The database was used to identify all ambulatory patients
diagnosed with a finding of GU(s) between 2001 and 2005.
Hospitalized patients were excluded because the most com-
mon indication for EGD in such patients is upper GI bleeding
(15), and endoscopists may be reluctant to biopsy an ulcer
in the setting of bleeding, markedly lowering the threshold
for surveillance EGD. Surveillance EGD was defined as any
EGD performed within 3 months of the index examination.
Exclusion criteria included: (i) history of gastric surgery;
(ii) history of gastric malignancy; or (iii) EGD performed
within the previous 12 months. These criteria were selected
to exclude patients at increased-risk of gastric cancer (who
might warrant intensive surveillance). Data were extracted
on: (i) patient age, gender, and race/ethnicity; (ii) practice
setting (community/HMO, academic, or VA/military); (iii)
geographic region; (iv) index ulcer size (<1 or ≥1 cm); (v)
whether the index ulcer was located in the antrum; and (vi)
whether the index ulcer was biopsied.
Statistical Analysis
Results were stratified by: (i) patient age, gender, and
race/ethnicity; (ii) index ulcer size and location; (iii) prac-
tice setting; and (iv) geographic region. Surveillance rates
between groups were compared statistically using Pearson’s
chi-square test statistic. Multivariate logistic regression was
performed to identify independent predictors of surveillance
EGD utilization. Adjusted odds ratios and 95% confidence
intervals are presented. An a priori determined P-value of
≤0.05 was considered statistically significant. All analyses
were performed using SAS version 9.1 software (SAS Insti-
tute, Inc., Cary, NC).
RESULTS
A total of 11,749 patients in the CORI database who un-
derwent EGD between 2001 and 2005 were found to have
one or more GUs on index EGD. For a variety of reasons,
5,636 patients were excluded (Fig. 1), resulting in 6,113 pa-
tients with GUs who were included in the study. Demographic
characteristics of the cohort are shown in Table 1. A specific
indication was reported for 86% of index EGDs, with the
vast majority of these (84%) being performed for upper gas-
trointestinal symptoms (51%) and suspected gastrointestinal
blood loss (33%). Patients diagnosed with a GU were more
likely to be females (56%), greater than 60 years old (57%),
and of non-Hispanic white ethnicity (80%). The vast majority
of procedures (68%) were performed in a community setting
(Table 2). Furthermore, biopsy was performed at nearly 70%
of index EGDs, a result that is concordant with previously
reported data (16). More than half of GUs were noted to be
<1 cm in size, and nearly 75% of patients had an ulcer in the
antrum. Multiplicity of ulcers and pathology results could not
be accurately determined from the database.
A total of 1,510 patients (24.7%, 95% CI 23.6–25.8%)
underwent surveillance EGD within 3 months of the index
EGD (Tables 3 and 4), and approximately 25% of patients
Gastric ulcer found on 
EGD (N = 11,749) 
Excluded (N = 5,636) 
• Non-ambulatory (N = 5,005) 
• EGD in previous year (N = 864) 
• Prior gastric surgery (N = 311) 
• Prior upper GI cancer (N = 42) 
Patients included in study 
(N = 6,113) 
Figure 1. Flowchart of selection process for inclusion in study.
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White non-Hispanic 4,875 79.8
Black non-Hispanic 422 6.9
Hispanic 500 8.2
Asian/Pacific Islander 148 2.4
Native American 82 1.3
Multi-racial 13 0.2
Not available 73 1.2
who underwent surveillance were found to have a GU on
surveillance examination (Table 5). GU surveillance was
explicitly reported as an indication in 78% of these pro-
cedures. Patients with an index ulcer >1 cm in size were
significantly more likely to also have a GU documented on
surveillance EGD (37.1% vs 18.1%, P < 0.0001). When the
definition of surveillance EGD was extended to any EGD
performed within 6 months of the index examination, the
proportion of patients undergoing surveillance increased to
almost 33%. The proportion of patients who were ultimately
found to have gastric cancer could not be determined from
the database.







North Central 508 8.3
North East 1,328 21.7
North West 867 14.2
South Central 603 9.9
South East 868 14.2
South West 1,939 31.7
Index ulcer size
<1 cm 3,137 51.3
≥1 cm 1,561 25.5







∗North Central = IN, MN, ND, NE; North East = MA, NJ, NY, OH, PA, VT; North
West = OR, WA; South Central = MS, OK, TN, TX; South East = FL, GA, KY, NC,
VA; South West = AZ, CA, CO, NM, NV.
Table 3. Proportion of Patients Undergoing Surveillance EGD




Female 788 23.2 0.002
Male 722 26.7
Age group (years)







White non-Hispanic 1,229 25.2 0.01
Black non-Hispanic 106 25.1
Hispanic 89 17.8
Asian/Pacific Islander 38 25.7
Native American 25 30.5
Multi-racial 2 15.4
Not available 21 28.8
∗These results include VA sites. When VA sites were excluded, gender was no longer
associated with surveillance utilization (P = 0.67).
In bivariate analysis, age (range 15.2–27.7%, P < 0.0001),
male gender (26.7% vs 23.2%., P = 0.002), race/ethnicity
(range 15.4–30.5%, P = 0.01), practice setting (range 20.4–
37.4%, P < 0.0001), geographic region (range 16.0–35.9%,
P < 0.0001), and index ulcer size >1 cm (32.8% vs 22.0%,
P < 0.0001) were each found to be significantly associated
with performance of surveillance EGD within 3 months of
the index examination (Tables 3 and 4). When VA sites (with
Table 4. Proportion of Patients Undergoing Surveillance EGD








North Central 131 35.9 <0.0001
North East 229 22.3
North West 129 23.6
South Central 34 16.0
South East 189 24.6
South West 258 20.7
Index ulcer size
<1 cm 689 22.0 <0.0001
≥1 cm 512 32.8
Not available 309 21.8
Antral ulcer
Yes 1,104 24.6 0.73
No 406 25.0
Ulcer biopsy taken
Yes 1,083 25.4 0.06
No 427 23.1
∗Community practices only (N = 4,166)
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Table 5. Proportion of Patients with Gastric Ulcer on Surveillance
EGD (Stratified by Index Ulcer Size)
Number %
Total 383 25.4
Index ulcer <1 cm 125 18.1
Index ulcer ≥1 cm 190 37.1∗
Index ulcer size missing 68 22.0
∗Chi-square P < 0.0001 (68 patients with missing data not included in this analysis).
predominantly male patients) were excluded, the aforemen-
tioned gender association was no longer significant (22.4%
vs 22.9%, P = 0.67). Furthermore, patients with antral
and nonantral ulcers underwent surveillance at similar rates
(24.6% vs 25.0%, P = 0.73). In multivariate analysis, only
age, practice setting, geographic region, and GU size were
found to be important predictors of surveillance EGD uti-
lization (Table 6). Notably, in contrast to the age-related in-
cidence of gastric cancer, surveillance utilization remained
remarkably stable across age groups, particularly among pa-
tient over 40 years of age (Fig. 2).
DISCUSSION
GUs are a common finding at upper EGD (1–3). Though the
vast majority of benign-appearing GUs are indeed benign (4,
5), approximately 5% of endoscopically benign-appearing
GUs harbor malignancy (6–8). Multiple ulcer biopsies at in-
dex EGD are highly sensitive for detecting malignancy (8, 9),
and these data are acknowledged by ASGE and ACG prac-
Table 6. Independent Predictors of Surveillance EGD Utilization
(Logistic Regression Analysis) (N = 6,113)
Odds Ratio 95% CI
Age group
<40 years 1.00 (reference)
40–49 years 1.48 1.10–2.00
50–59 years 1.65 1.25–2.18
60–69 years 1.81 1.38–2.38
70–79 years 1.95 1.48–2.56






North Central 1.00 (reference)
North East 0.52 0.41–0.65
North West 0.50 0.39–0.64
South Central 0.32 0.24–0.43
South East 0.56 0.44–0.72
South West 0.47 0.37–0.58
Index ulcer size
<1 cm 1.00 (reference)
≥1 cm 1.88 1.64–2.16




tice guidelines and by the ASGE/ACG Task Force on Quality
of Endoscopy (10, 17, 18). Furthermore, no major U.S. pro-
fessional gastroenterology society recommends surveillance
of GUs. However, a recent Canadian survey suggested that
nearly two-thirds of endoscopists choose to routinely per-
form surveillance EGD to document GU healing (11). Using
the CORI database, our study demonstrates that U.S. endo-
scopists perform surveillance EGD within 3 months in ap-
proximately 25% of patients diagnosed with a GU. When the
time interval was extended from 3 to 6 months, the propor-
tion of patients undergoing surveillance EGD increased to
almost 33%. It should be noted that these numbers likely rep-
resent minimum estimates, as patients may undergo surveil-
lance EGD at a non-CORI site. In multivariate analysis, the
surveillance rate varied significantly across age groups, prac-
tice setting, and geographic region. Most notably, patients
under age 40 (15%), those with small index ulcers (22%),
those with antral ulcers (25%), and those within the VA sys-
tem (37%) appear to undergo surveillance at higher than ex-
pected rates, which suggests overuse of surveillance EGD. Of
note, our comparison of age-specific GU surveillance rates
to age-specific gastric cancer incidence (SEER registry) is
somewhat limited by the fact that our study included only
ambulatory patients (as opposed to the SEER registry, which
includes all-comers).
The management of GUs has been a controversial topic in
gastroenterology for well over two decades. The first study to
challenge the necessity of surveillance EGD was published 25
years ago by Graham et al. (9). This study demonstrated that
obtaining at least seven biopsy specimens of the index ulcer
was sufficient to exclude underlying malignancy. However,
subsequent studies raised concerns that malignancy could be
missed despite index biopsies and that missing early gastric
cancer could lead to poorer long-term outcomes (7, 19). In-
deed, a 1991 study of endoscopic surveillance of GUs was
carried out under the assumption that such surveillance was
a “mandatory” practice (20). This study found that surveil-
lance EGD was also imperfect in excluding gastric cancer,
with up to one-third of gastric cancer cases being missed de-
spite endoscopic surveillance. A subsequent study in 1993 by
Pruitt et al. concluded that surveillance EGD was unneces-
sary provided that sufficient biopsy specimens were obtained
at the index examination (8). In 1997, a U.S. study from a
single tertiary referral center utilized an endoscopic database
to determine the sensitivity and specificity of endoscopists’
visual impression in predicting the pathology of GUs. As a
secondary aim, this study reported surveillance rates, finding
these to be very low (11%), though the authors concluded that
this was likely related to incomplete follow-up of the patient
population. The generalizability of results from a tertiary re-
ferral center is also questionable. It was not until 1999 that
a study was performed specifically to assess how gastroen-
terologists manage benign-appearing GUs. In this survey-
based study, nearly 60% of Canadian gastroenterologists re-
ported performing surveillance EGD routinely in patients
with benign-appearing GUs (11). To our knowledge, our
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Figure 2. Surveillance utilization (%, blue) and gastric cancer incidence (cases per 1,000, red) (SEER 17, http://seer.cancer.gov/faststats/,
accessed October 25, 2007).
study is the first since this 1999 study to assess how gastroen-
terologists manage benign-appearing GUs. Furthermore,
our study is the first since the 1997 study to report actual
rather than self-reported practice patterns specifically on this
topic and is also the first ever study reporting practice patterns
across the United States. Like the Canadian study, our study
suggests continued overuse of surveillance EGD in patients
with benign-appearing GUs. Potential reasons for this finding
include lack of knowledge or disagreement with guidelines,
medico-legal concerns, and financial incentives. As gastroen-
terologists in the United States face increasing demand for
endoscopic services and experts project that this demand will
continue to increase, decreasing overuse of EGD will assume
increasing importance (21–24).
Several limitations and strengths of our study deserve men-
tion. First, this was a retrospective study. Though we at-
tempted to control for confounders in our analysis, the po-
tential for unmeasured confounding and bias remains. In ad-
dition, CORI does not reliably record specific endoscopic
details, such as ulcer location, number of ulcers, and pathol-
ogy data, or clinical information about individual patients
outside of the EGD report. We therefore were unable to re-
port or account for these factors in our analysis. Finally, our
study may have suffered from loss to follow-up. Patients who
undergo index EGD at a center that participates in CORI
are free to undergo additional endoscopic examinations at a
non-CORI site. This may have resulted in incomplete cap-
ture of our patient population, meaning that the proportion
of patients who undergo surveillance within 3 months may
actually be greater than 25%. This phenomenon may partly
explain the significantly higher rate of surveillance observed
in VA centers in our study. VA patients may be less likely
to follow-up at a non-CORI site for their surveillance EGD,
resulting in more complete follow-up (and therefore higher
surveillance rates) in this subgroup of patients. Alternatively,
our study could have overestimated the proportion of patients
undergoing surveillance due to the definition of surveillance
EGD that was used (any EGD performed within 3 months
of index EGD). This may have particularly affected the re-
sults for older patients, overestimating the surveillance rates
in these patients. However, this would have weakened the
observed age-related surveillance gradient, further strength-
ening our conclusion that younger patients undergo surveil-
lance at disproportionately higher rates than warranted based
on underlying gastric cancer incidence. Using only EGDs
with a documented indication of “GU surveillance” (a less
sensitive but more specific definition for “surveillance EGD”
than that used in our primary analysis), the overall surveil-
lance rate was 19.3%. One of the important strengths of our
study is the use of actual rather than self-reported practice
patterns. Furthermore, we used data collected from a wide
variety of practice settings that is representative of EGD in
Medicare patients in the United States today (12). Finally,
our study was performed after the publication of ACG and
ASGE guidelines supporting the use of multiple biopsies, al-
lowing us to draw conclusions regarding the uptake of these
guidelines into clinical practice (17, 18).
In summary, approximately 25% of ambulatory patients
diagnosed with GUs undergo surveillance EGD within 3
months. This rate varies significantly by patient age, ul-
cer size, practice setting, and geographic location. How-
ever, young patients, those with small ulcers, those with
antral ulcers, and those within the VA system continue to
undergo surveillance at higher than expected rates, suggest-
ing overuse of surveillance EGD. Future studies should use
patient-specific risk factors for gastric cancer to define a
tailored approach to excluding malignancy in patients with
benign-appearing GUs.
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STUDY HIGHLIGHTS
What Is Current Knowledge
 Benign-appearing gastric ulcers are unlikely to be ma-
lignant.
 Guidelines recommend that all gastric ulcers be biop-
sied.
 Guidelines do not specifically recommend surveillance
EGD.
What Is New Here
 U.S. endoscopists perform surveillance in approxi-
mately 25% of patients.
 Surveillance rates do not increase appropriately as gas-
tric cancer risk increases.
 Surveillance EGD appears to be overused in the United
States.
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